Literature DB >> 10548588

Detection of borreliacidal antibodies in Lyme borreliosis patient sera containing antimicrobial agents.

D A Jobe1, N Rawal, R F Schell, S M Callister.   

Abstract

The borreliacidal-antibody test has been used for the serological detection and confirmation of Lyme borreliosis. However, the presence of antimicrobial agents in serum can confound the accurate detection of borreliacidal antibodies. In this study, we developed a Bacillus subtilis agar diffusion bioassay to detect small concentrations of antimicrobial agents in serum. We also used XAD-16, a nonionic polymeric resin, to adsorb and remove high concentrations of amoxicillin, cefotaxime, ceftriaxone, cefuroxime, doxycycline, and erythromycin without significantly affecting even small concentrations of immunoglobulin M (IgM) or IgG borreliacidal antibodies. High concentrations of penicillin could also be removed by adding 1 U of penicillinase without significantly influencing the levels of borreliacidal antibodies. These simple procedures greatly enhance the clinical utility of the borreliacidal-antibody test.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548588      PMCID: PMC95800          DOI: 10.1128/CDLI.6.6.930-933.1999

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  25 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Rapid isolation of bacteria from septicemic patients by use of an antimicrobial agent removal device.

Authors:  C Wallis; J L Melnick; R D Wende; P E Riely
Journal:  J Clin Microbiol       Date:  1980-05       Impact factor: 5.948

3.  The antimicrobial removal device. A microbiological and clinical evaluation.

Authors:  A J Wright; R L Thompson; C A McLimans; W R Wilson; J A Washington
Journal:  Am J Clin Pathol       Date:  1982-08       Impact factor: 2.493

4.  Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

Authors:  J C Rousselle; S M Callister; R F Schell; S D Lovrich; D A Jobe; J A Marks; C A Wieneke
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

5.  Elimination of quinolone antibiotic carryover through use of antibiotic-removal beads.

Authors:  R A Zabinski; A J Larsson; K J Walker; S S Gilliland; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

6.  Lyme disease assay which detects killed Borrelia burgdorferi.

Authors:  S M Callister; R F Schell; S D Lovrich
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

7.  In vitro and in vivo susceptibility of Borrelia burgdorferi.

Authors:  V P Mursic; B Wilske; G Schierz; M Holmburger; E Süss
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

8.  Characterization of the borreliacidal antibody response to Borrelia burgdorferi in humans: a serodiagnostic test.

Authors:  S M Callister; R F Schell; K L Case; S D Lovrich; S P Day
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

9.  In vitro inhibition of Borrelia burgdorferi growth by antibodies.

Authors:  A Sadziene; P A Thompson; A G Barbour
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

10.  In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone.

Authors:  W A Agger; S M Callister; D A Jobe
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

View more
  1 in total

1.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.